In vivo Characterization of the Opioid Receptor–Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations

INTRODUCTION: The atypical antipsychotic olanzapine is approved for the treatment of schizophrenia and bipolar I disorder; however, weight gain and metabolic dysregulation associated with olanzapine therapy have limited its clinical utility. In clinical studies, treatment with the combination of ola...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Laura A, Gajipara, Nileshkumar, Sun, Lei, Bacolod, Maria, Zhou, Ying, Namchuk, Mark, Cunningham, Jacobi I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636859/
https://www.ncbi.nlm.nih.gov/pubmed/36345421
http://dx.doi.org/10.2147/NDT.S373195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636859/
https://www.ncbi.nlm.nih.gov/pubmed/36345421
http://dx.doi.org/10.2147/NDT.S373195

Ejemplares similares